|1.||Kurimoto, Masanori: 1 article (01/2003)|
|2.||Endo, Shunro: 1 article (01/2003)|
|3.||Hirashima, Yutaka: 1 article (01/2003)|
|4.||Hamada, Hideo: 1 article (01/2003)|
|5.||Nagai, Shoichi: 1 article (01/2003)|
|6.||Hayashi, Nakamasa: 1 article (01/2003)|
|7.||Kamiyama, Hironaga: 1 article (01/2003)|
|1.||Astrocytoma (Pilocytic Astrocytoma)
01/01/2003 - "The potential clinical use of B1620 could be expanded to malignant astrocytomas."
01/01/2003 - "B1620 inhibited anchorage-dependent growth of six astrocytoma cell lines with a median effective dose (IC50) ranging from 2.0 to 20.7 microM. "
01/01/2003 - "This study demonstrates that Ras pathway inactivation by a farnesyltransferase inhibitor, B1620, effectively inhibits in vitro and in vivo growth of human astrocytoma cells, although normal human astrocytes (NHA) derived from fetal brain are resistant to B1620. "
01/01/2003 - "All astrocytoma cells showed apoptotic figures after Hoechst 33258 staining, when treated for 5 days at each IC50 concentration against B1620. "
01/01/2003 - "Anti-proliferative effect of B1620 on in vitro growth of astrocytoma cells was examined by MTT assays and soft agar colony formation assay. "
|2.||Bisbenzimidazole (Hoechst 33258)
|1.||Heterologous Transplantation (Xenotransplantation)